| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Ming Hsieh
Chief Executive Officer and Chairperson of the Board
|
70 | Not stated | Not stated | Not reported | |
|
Paul Kim
Chief Financial Officer
|
58 |
Since 2016
10 years
|
Not stated | $2,773,352 | |
|
Hanlin Gao
Chief Scientific Officer and Laboratory Director
|
59 | Not stated | Not stated | $2,352,249 | |
|
Jian Xie
President and Chief Operating Officer
|
59 | Not stated | Not stated | $2,807,658 | |
|
Ming Hsieh
Chief Executive Officer
Title from the Form 4 dated Sep 1, 2026
|
Not stated | Not stated | Not stated | Not reported | |
|
Ming Hsieh
Also a director
Chief Executive Officer
|
Not stated | Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Drug-related licensing and development services and equipment purchases from ANP, incurred before April 25, 2025
Employee service agreement with ANP entered April 2023; revenue recognized from ANP
Acquisition by the Company of 100% of the outstanding equity of ANP, including settlement of outstanding liabilities and receivables
Company performs genetic testing and other testing services on an arm's-length basis for AHMC
Loading...
